What Kryxana is?
Kryxana 200 mg (Ribociclib) is a cyclin-dependent kinase inhibitor, indicated to use with the combination of the aromatase inhibitor to treat HR-Positive and HER2-Negative advanced as well as metastatic breast cancer. This FDA approved medication was developed by Novartis.
What Ribociclib is?
Ribociclib was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the European Medicines Agency (EMA) in August 2017, for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers.
Ribociclib, sold under the brand name Kisqali, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.